Journal
RADIOTHERAPY AND ONCOLOGY
Volume 115, Issue 2, Pages 264-271Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.radonc.2015.03.023
Keywords
30 day mortality; Palliative radiotherapy; Clinical indicator; Fractionation
Funding
- Medical Research Council [MR/L01629X/1]
- Cancer Research UK (CRUK) Bobby Moore Fund [C23434/A9805]
- CRUK [C37059/A16369]
- Cancer Research UK [9805] Funding Source: researchfish
- Medical Research Council [MR/L01629X/1] Funding Source: researchfish
- MRC [MR/L01629X/1] Funding Source: UKRI
Ask authors/readers for more resources
Background: 30-day mortality (30DM) has been suggested as a clinical indicator of the avoidance of harm in palliative radiotherapy within the NHS, but no large-scale population-based studies exist. This large retrospective cohort study aims to investigate the factors that influence 30DM following palliative radiotherapy and consider its value as a clinical indicator. Methods: All radiotherapy episodes delivered in a large UK cancer centre between January 2004 and April 2011 were analysed. Patterns of palliative radiotherapy, 30DM and the variables affecting 30DM were assessed. The impact of these variables was assessed using logistic regression. Results: 14,972 palliative episodes were analysed. 6334 (42.3%) treatments were delivered to bone metastases, 2356 (15 7%) to the chest for lung cancer and 915 (5.7%) to the brain. Median treatment time was 1 day (IQR 1-7). Overall 30DM was 12.3%. Factors having a significant impact upon 30DM were sex, primary diagnosis, treatment site and fractionation schedule (p < 0.01). Conclusion: This is the first large-scale description of 30-day mortality for unselected adult palliative radiotherapy treatments. The observed differences in early mortality by fractionation support the use of this measure in assessing clinical decision making in palliative radiotherapy and require further study in other centres and health care systems. (C) 2015 The Authors. Published by Elsevier Ireland Ltd.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available